Clinical Trial

A Study to Determine the Safety and Tolerability of AG-236 and How it is Absorbed, Broken Down, and Eliminated From the Body in Healthy Participants

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The primary purpose of this study is to assess the safety and tolerability of a single dose of AG-236 administered subcutaneously in healthy participants.
Protocol Amendment History 2 changes
critical Trial status changed: Recruiting → Active, Not Recruiting 2026-04-30
notable Primary completion moved earlier: 2026-03-25 -> 2026-02-11 2026-04-30
Trial Details
NCT Number NCT07075640
Lead Sponsor Agios Pharmaceuticals, Inc.
Conditions Healthy Participants
Enrollment 24 participants
Start Date 2025-07-07
Primary Completion 2026-02-11 (estimated)
Study Completion 2026-08-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-30